RT @_TanyaBondar_: And the question of COVID in cancer came up again in Q&A. As @DMadduri and teams across NYC recently reported in two stu…
And the question of COVID in cancer came up again in Q&A. As @DMadduri and teams across NYC recently reported in two studies, there was no increased SARS-CoV-2 susceptibility in #myeloma patients: https://t.co/BA22XHfWeX https://t.co/surjDANop0
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward [Jul 14, 2020] Wang et al. J Hematol Oncol https://t.co/jHoXJC4RmT #mmsm #CCC19 #COVID19nCancer #2019nCoV #COVID19 @COVID19nCCC New York, n=58 MM
RT @ovanoekelen: @mtmdphd @humberto0927 @rubinstein_md @hemoncwarner @COVID19nCCC @MayoMyeloma @bhemato Here is more data from Mount Sinai'…
@mtmdphd @humberto0927 @rubinstein_md @hemoncwarner @COVID19nCCC @MayoMyeloma @bhemato Here is more data from Mount Sinai's cohort! (n = 58) https://t.co/GPfeFzLdIl
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward [Jul 14, 2020] Wang et al. J Hematol Oncol https://t.co/jHoXJC4RmT #mmsm #CCC19 #COVID19nCancer #2019nCoV #COVID19 @COVID19nCCC New York, n=58 MM
RT @mtmdphd: A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward [Jul 14, 2020] W…
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward [Jul 14, 2020] Wang et al. J Hematol Oncol https://t.co/jHoXJC4RmT #mmsm #CCC19 #COVID19nCancer #2019nCoV #COVID19 @COVID19nCCC New York, n=58 MM
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward | Journal of Hematology & Oncology | Full Text https://t.co/8EbVgcn9T8
RT @TischCancer: .@DMadduri, et al. report on characteristics of #COVID19 among patients with #MYELOMA and their serological responses. ht…
RT @TischCancer: .@DMadduri, et al. report on characteristics of #COVID19 among patients with #MYELOMA and their serological responses. ht…
RT @TischCancer: .@DMadduri, et al. report on characteristics of #COVID19 among patients with #MYELOMA and their serological responses. ht…
RT @TischCancer: .@DMadduri, et al. report on characteristics of #COVID19 among patients with #MYELOMA and their serological responses. ht…
.@DMadduri, et al. report on characteristics of #COVID19 among patients with #MYELOMA and their serological responses. https://t.co/qYLqPCWGIa https://t.co/z9qqrxjpzL @IcahnMountSinai @JoshuaRichterMD @MiriamMerad @tarekmd91 @ovanoekelen @HJChoMDPhD1
RT @TischCancer: Study by @DMadduri, et al. provides analysis of 58 #myeloma and SMM pts who developed #COVID19. Myeloma therapy and immun…
RT @TischCancer: Study by @DMadduri, et al. provides analysis of 58 #myeloma and SMM pts who developed #COVID19. Myeloma therapy and immun…
RT @JoshuaRichterMD: A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward | Journa…
RT @TischCancer: Study by @DMadduri, et al. provides analysis of 58 #myeloma and SMM pts who developed #COVID19. Myeloma therapy and immun…
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward [Jul 14, 2020] Wang et al. J Hematol Oncol https://t.co/jHoXJC4RmT #mmsm #CCC19 #COVID19nCancer #2019nCoV #COVID19 @COVID19nCCC New York, n=58 MM
RT @TischCancer: Study by @DMadduri, et al. provides analysis of 58 #myeloma and SMM pts who developed #COVID19. Myeloma therapy and immun…
547/ New York City, USA (adult smoking rate was 13.4% in 2017) Of 57 people with multiple myeloma who received a positive diagnosis, 36.8% were current or former smokers (CFS) Of 35 of them hospitalized, CFS=42.9% Of 14 who died, CFS=50% Continued ht
RT @TischCancer: Study by @DMadduri, et al. provides analysis of 58 #myeloma and SMM pts who developed #COVID19. Myeloma therapy and immun…
New article: A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward. https://t.co/1BCtH6gmHl #MMSM #MultipleMyeloma #hematology https://t.co/NrDduDDG4L
RT @TischCancer: Study by @DMadduri, et al. provides analysis of 58 #myeloma and SMM pts who developed #COVID19. Myeloma therapy and immun…
RT @TischCancer: Study by @DMadduri, et al. provides analysis of 58 #myeloma and SMM pts who developed #COVID19. Myeloma therapy and immun…
RT @JoshuaRichterMD: A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward | Journa…
RT @TischCancer: Study by @DMadduri, et al. provides analysis of 58 #myeloma and SMM pts who developed #COVID19. Myeloma therapy and immun…
RT @JoshuaRichterMD: A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward | Journa…
#COVID19 NEWS | Being on active #myeloma tx (81%) or immunoparesis (89%), were not associated with higher mortality in patients treated at @MountSinaiNYC. Grade 3 lymphopenia and not achieving a CR were associated with a ⬆️risk of hospitalization #mmsm ht
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward [Jul 14, 2020] Wang et al. J Hematol Oncol https://t.co/jHoXJC4RmT #mmsm #CCC19 #COVID19nCancer #2019nCoV #COVID19 @COVID19nCCC New York, n=58 MM
RT @TischCancer: Study by @DMadduri, et al. provides analysis of 58 #myeloma and SMM pts who developed #COVID19. Myeloma therapy and immun…
Study by @DMadduri, et al. provides analysis of 58 #myeloma and SMM pts who developed #COVID19. Myeloma therapy and immunoparesis did not influence outcomes. https://t.co/N0qNCu2mOS @JoshuaRichterMD @MiriamMerad @tarekmd91 @HJChoMDPhD1 @ovanoekelen https
RT @JoshuaRichterMD: A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward | Journa…
RT @BoWangMD1: Our full print article highlighting our experiences with multiple myeloma patients who developed COVID-19, available on JHO.…
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward | Journal of Hematology & Oncology | Full Text. Proud to be part of this team @TischCancer @DMadduri #mmsm https://t.co/E9EOQAsOzl
Our full print article highlighting our experiences with multiple myeloma patients who developed COVID-19, available on JHO. The fight against COVID-19 continues onward! https://t.co/8fWCAug7ey @TischCancer @SinaiImmunol